THE BTK INHIBITOR PCI-32765 SYNERGISTICALLY INCREASES PROTEASOME INHIBITOR ACTIVITY IN DLBCL AND MCL CELLS SENSITIVE OR RESISTANT TO BORTEZOMIB

Interactions between the Bruton tyrosine kinase (BTK) inhibitor PCI-32765 and the proteasome inhibitor (bortezomib) were examined in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells, including those highly resistant to bortezomib. Co-administration of PCI-32765/bortezomib s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dasmahapatra, Girija, Patel, Hiral, Dent, Paul, Fisher, Richard I., Friedberg, Jonathan, Grant, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3739300/
https://ncbi.nlm.nih.gov/pubmed/23360303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12206
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados